{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:06:13Z","timestamp":1788548773598,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejca.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T17:41:23Z","timestamp":1630172483000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3025-6096","authenticated-orcid":false,"given":"Se-Il","family":"Go","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Kyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Young","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung Soon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1106-8030","authenticated-orcid":false,"given":"Jung Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanggon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jin","family":"Sym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-134X","authenticated-orcid":false,"given":"Yaewon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-0333","authenticated-orcid":false,"given":"In Gyu","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.08.002_bib1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib2","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.08.002_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.08.002_bib5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12501","article-title":"Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"105","author":"Okusaka","year":"2014","journal-title":"Canc Sci"},{"key":"10.1016\/j.ejca.2021.08.002_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.08.002_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.08.002_bib8","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib9","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/bjc.2015.103","article-title":"Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer","volume":"112","author":"Ohkawa","year":"2015","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.08.002_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/bjc.2016.436","article-title":"Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer","volume":"116","author":"Ioka","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.08.002_bib11","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4251\/wjgo.v10.i12.505","article-title":"Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer","volume":"10","author":"Chung","year":"2018","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MPA.0000000000001534","article-title":"FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure","volume":"49","author":"Matsumoto","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.ejca.2021.08.002_bib14","first-page":"32","article-title":"Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study","volume":"38","author":"Kim","year":"2018","journal-title":"Canc Commun"},{"key":"10.1016\/j.ejca.2021.08.002_bib15","first-page":"814","article-title":"Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience","volume":"61","author":"Umemura","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ejca.2021.08.002_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.08.002_bib17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjc.6602687","article-title":"Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer","volume":"93","author":"Ko","year":"2005","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.08.002_bib18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11136-012-0217-4","article-title":"Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer","volume":"22","author":"Cella","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2021.08.002_bib19","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","article-title":"Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire","volume":"20","author":"Heffernan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/annonc\/mdj072","article-title":"Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma","volume":"17","author":"Steel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.08.002_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.08.002_bib23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1634\/theoncologist.2014-0223","article-title":"S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study","volume":"19","author":"Ge","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.08.002_bib24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/annonc\/mdv603","article-title":"A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"27","author":"Ueno","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.08.002_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","article-title":"A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer","volume":"63","author":"Morizane","year":"2009","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2021.08.002_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00280-010-1311-3","article-title":"Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer","volume":"67","author":"Sudo","year":"2011","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2021.08.002_bib27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.pan.2020.07.006","article-title":"FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: a subset analysis of data from a nationwide multicenter observational study in Japan","volume":"20","author":"Kobayashi","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejca.2021.08.002_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12885-020-06945-8","article-title":"Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer","volume":"20","author":"Sawada","year":"2020","journal-title":"BMC Canc"},{"key":"10.1016\/j.ejca.2021.08.002_bib29","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3748\/wjg.v27.i17.1847","article-title":"Pancreatic adenocarcinoma: beyond first line, where are we?","volume":"27","author":"Cherri","year":"2021","journal-title":"World J Gastroenterol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921005104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:03Z","timestamp":1760733183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921005104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":29,"alternative-id":["S0959804921005104"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}